BusinessHemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS DiseaseBy Nasdaq OMXApr 4, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)By Nasdaq OMXJan 20, 2016, 1:30 PM UTC
